UAB Ferentis and UAB Experimentica have been awarded a new grant under the program foreseen for supporting R&D at companies, under the European Regional Development Fund 2014–2020 m. The project is aimed at developing an innovative method of corneal transplantation and the development of biosynthetic cornea for regenerative medicine. At the same time, an artificial model simulating the human cornea for drug penetration tests will be developed.
As the research platform, Ferentis is further advancing its proprietary extracellular matrix mimicking platform, that is based on crosslinked peptide hydrogel and microfabrication technologies. The total approved budget for the three-year project is close to EUR 1 522 020, including the awarded grant support, EUR 1 098 484. More details are available
here (in Lithuanian).
